The ALOX12 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of PaTu 8988t cells carrying a targeted disruption of the ALOX12 gene. This loss-of-function model abrogates arachidonate 12-lipoxygenase expression, enabling robust investigation of ALOX12-dependent processes in pancreatic cancer. The polyclonal format ensures a heterogeneous allelic disruption, minimizing clonal bias for population-level phenotypic analyses.
The parental PaTu 8988t cell line is a human pancreatic ductal adenocarcinoma line isolated from a liver metastasis. Exhibiting epithelial morphology and oncogenic KRAS mutations, it recapitulates aggressive PDAC features. Its metastatic origin renders it especially pertinent for studying molecular drivers of pancreatic cancer progression, invasion, and therapeutic resistance, making it an excellent host for CRISPR/Cas9-mediated gene knockout.
ALOX12 encodes arachidonate 12-lipoxygenase, which oxygenates arachidonic acid to 12-HETE, a lipid mediator that binds the GPR31 receptor and activates PI3K/Akt and ERK1/2 signaling. This promotes cell proliferation via Cyclin D1 and survival via Bcl-2 family proteins. Upstream, ALOX12 expression is induced by cytokines (IL-4, IL-13), oncogenic KRAS, and MAPK-responsive transcription factors Sp1 and AP-1. Interactions with PEBP1 and ALOX5AP facilitate membrane phospholipid engagement, while GPX4 antagonizes ALOX12-mediated lipid peroxidation, positioning the enzyme at the intersection of mitogenic and ferroptotic pathways.
In PaTu 8988t cells, ALOX12-generated 12-HETE drives oncogenic signaling; its disruption attenuates GPR31-mediated PI3K/Akt and ERK activation, reducing proliferation and migration. Additionally, ALOX12 knockout alters ferroptosis sensitivity by diminishing pro-ferroptotic lipid hydroperoxide production, thereby affecting the balance with GPX4-mediated detoxification. This model clarifies ALOX12-specific roles in pancreatic cancer survival, metastatic potential, and ferroptosis regulation, independent of clonal variations.
Applications include Western blotting and RT-qPCR for knockout validation, LC-MS/MS for 12-HETE profiling, MTS/BrdU proliferation assays, wound healing migration tests, and colony formation studies. Ferroptosis can be assessed via C11-BODIPY lipid ROS detection combined with inhibitor rescue. Phospho-Akt and phospho-ERK analyses by flow cytometry or western blotting elucidate signaling changes. This polyclonal knockout model serves as a versatile tool for pancreatic cancer signaling and ferroptosis research. For further information, contact Ascent Research.
